Treatment of delirium with risperidone in cancer patients

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 5, 2012, Pages 411-417

  Kishi, Yasuhiro ^a,b,f   Kato, Masashi ^b,c   Okuyama, Toru ^b,d   Thurber, Steven ^e,f  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e Woodlands Center   (United States)

^f Itasca Brain Behavioral Science Society   (United States)

Author keywords

cancer; delirium; pharmacotherapy; risperidone; treatment

Indexed keywords

RISPERIDONE;

ADULT; AGE; AGED; AGITATION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COGNITIVE DEFECT; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENDER; HUMAN; MALE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELIRIUM; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PSYCHOMOTOR AGITATION; RISPERIDONE; SLEEP DISORDERS, CIRCADIAN RHYTHM; TREATMENT OUTCOME;

EID: 84864415407     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2012.02346.x     Document Type: Article

References (26)

1. Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J,. Cognitive failure in patients with terminal cancer: A prospective study. J. Pain Symptom Manage. 1992; 7: 192-195.
2. Lawlor PG, Gagnon B, Mancini IL, et al,. Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. Arch. Intern. Med. 2000; 160: 786-794. (Pubitemid 30165239)
3. Han CS, Kim YK,. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45: 297-301.
4. Breitbart W, Marotta R, Platt MM, et al,. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am. J. Psychiatry 1996; 153: 231-237. (Pubitemid 26038965)
5. Lonergan E, Britton AM, Luxenberg J, Wyller T,. Antipsychotics for delirium. Cochrane Database Syst. Rev. 2007; (18): CD005594.
6. Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N,. Validation of the Delirium Rating Scale-revised-98: Comparison with the delirium rating scale and the cognitive test for delirium. J. Neuropsychiatry Clin. Neurosci. 2001; 13: 229-242. (Pubitemid 32499675)
7. Kato M, Kishi Y, Okuyama T, Trzepacz PT, Hosaka T,. Japanese version of the Delirium Rating Scale, Revised-98 (DRS-R98-J): Reliability and validity. Psychosomatics 2010; 51: 425-431.
8. Trzepacz PT, Bourne R, Zhang S,. Designing clinical trials for the treatment of delirium. J. Psychosom. Res. 2008; 65: 299-307.
9. Folstein MF, Folstein SE, McHugh PR,. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975; 12: 189-198.
10. Mori E, Mitani Y, Yamadori A,. The validity of Japanese version of Mini-Mental State Examination in patients with nervous disorder. Shinkei Shinri 1985; 1: 2-10 (in Japanese).
11. Guy W,. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare, Rockville, MD, 1976; 217-222.
12. Knaus WA, Wagner DP, Draper EA, et al,. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-1636.
13. Naughton BJ, Moran MB, Kadah H, Heman-Ackah Y, Longano J,. Delirium and other cognitive impairment in older adults in an emergency department. Ann. Emerg. Med. 1995; 25: 751-755.
14. Roberts B, Rickard CM, Rajbhandari D, et al,. Multicentre study of delirium in ICU patients using a simple screening tool. Aust. Crit. Care 2005; 18: 6, 8- 9, 11-14 passim.
15. Pandharipande P, Shintani A, Peterson J, et al,. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104: 21-26.
16. Oken MM, Creech RH, Tormey DC, et al,. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649-655. (Pubitemid 13149996)
17. Inaba T,. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Seiwa Publishers, Tokyo, 1996 (in Japanese).
18. Patel RP, Gambrell M, Speroff T, et al,. Delirium and sedation in the intensive care unit: Survey of behaviors and attitudes of 1384 healthcare professionals. Crit. Care Med. 2009; 37: 825-832.
19. Hatta K,. The practice of treatment for delirium in Japan. In: 6th Annual Meeting of the International College of Geriatric Psychoneuropharmacology, International College of Geriatric Psychoneuropharmacology, Hiroshima, 2006; 101.
20. U.S. Food and Drug Administration. FDA alert. Conventional Antipsychotics-Healthcare Professional Sheet text version. 2008. [Cited 16 June 2008.] Available from URL: (last accessed 21 March 2012).
21. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, Kaci L, Schneeweiss S,. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J. Am. Geriatr. Soc. 2008; 56: 1644-1650.
22. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V,. Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011; 68: 128-137.
23. Tost H, Braus DF, Hakimi S, et al,. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat. Neurosci. 2010; 13: 920-922.
24. Meagher D, Moran M, Raju B, et al,. A new data-based motor subtype schema for delirium. J. Neuropsychiatry Clin. Neurosci. 2008; 20: 185-193.
25. Horikawa N, Yamazaki T, Miyamoto K, et al,. Treatment for delirium with risperidone: Results of a prospective open trial with 10 patients. Gen. Hosp. Psychiatry 2003; 25: 289-292. (Pubitemid 36802275)
26. Mittal D, Jimerson NA, Neely EP, et al,. Risperidone in the treatment of delirium: Results from a prospective open-label trial. J. Clin. Psychiatry 2004; 65: 662-667.